Freenome vs GRAIL
The blood based cancer screening choice is really a choice of screening philosophy. GRAIL's Galleri is the multi cancer bet: a single draw screening for signals across more than 50 cancer types with tissue of origin prediction, backed by the deepest trial program in the space, PATHFINDER 2 at 25,490 participants and the NHS Galleri trial at more than 140,000, the only prospective randomised controlled trial of multi cancer early detection for population screening. Freenome is the single cancer depth play: SimpleScreen CRC targets colorectal screening specifically, with the PREEMPT CRC validation published in JAMA and blood based testing added to the American Cancer Society's colorectal guideline in 2026, commercialised through Exact Sciences and Abbott. Neither test is FDA approved: Galleri is offered as a laboratory developed test with its final PMA module submitted in January 2026, and SimpleScreen CRC's PMA has been under review since August 2025. If your failure mode is cancers no screening program looks for, start with GRAIL. If your failure mode is the colorectal screening gap specifically, start with Freenome.
- Colorectal is the specific gap you are closing: SimpleScreen CRC reported 85 percent sensitivity for colorectal cancer at 90 percent specificity in a 966 sample head to head validation, with the PREEMPT CRC study published in JAMA in 2025.
- Guideline tailwind: blood based colorectal screening entered the American Cancer Society's updated guideline in 2026, the recognition path a payer conversation runs on.
- Commercial machinery already attached: Exact Sciences holds exclusive US commercial rights and a separate Abbott collaboration covers bringing the test to market.
- Breadth is the argument: a signal across more than 50 cancer types with tissue of origin prediction from one draw, covering the cancers that have no standalone screening program.
- Trial scale no rival matches: PATHFINDER 2 enrolled 25,490 participants and NHS Galleri enrolled more than 140,000, the only prospective randomised controlled trial of a multi cancer early detection test for population screening.
- Regulatory momentum with a public evidence trail: the final PMA module was submitted in January 2026 on a test holding Breakthrough Device designation since 2018, available today as a laboratory developed test.
Side-by-Side
| Axis | F Freenome |
G GRAIL |
|---|---|---|
| AI Centrality | ||
| Autonomy and Oversight Model | — | — |
| Model and Technology Transparency | — | — |
| Clinical and Operational Evidence | ||
| AI Safety and PHI Stewardship | — | — |
| HIPAA and BAA Posture | — | — |
| Security Certifications and Trust Center | — | — |
| FDA and Regulatory Status | ||
| AI Governance and Bias Disclosure | — | — |
| EHR and Interoperability Depth | — | — |
| Deployment Model and Data Residency | — | — |
| Commercial Transparency | ||
| Setting and Specialty Coverage |
Neither test is FDA approved. Galleri is offered as a laboratory developed test; SimpleScreen CRC is pending its PMA decision, anticipated in 2026, and its PMA has been under review since August 2025. Freenome's 22 percent sensitivity for advanced precancerous lesions at 90 percent specificity, from the same validation as the 85 percent cancer sensitivity figure, is a number screening committees should weigh alongside the headline result. Breakthrough Device designation is not approval. Sensitivity figures for both vendors come from company reported studies; NHS Galleri results should be read from the trial's own publications.